title: Antithrombotic properties of SSR182289A, a new, orally active thrombin inhibitor.
abstract: N-[3-[[[(1S)-4-(5-Amino-2-pyridinyl)-1-[[4-difluoromethylene)-1-piperidinyl]carbonyl]butyl]amino]sulfonyl][1,1'-biphenyl]-2-yl]acetamide hydrochloride (SSR182289A) is a novel, potent, and selective thrombin inhibitor. We have examined the antithrombotic properties of SSR182289A administered by i.v. and p.o. routes in several different animal thrombosis models in comparison with reference antithrombotic agents. Oral administration of SSR182289A produced dose-related antithrombotic effects in the following models; rat venous thrombosis (ED(50) 0.9 mg/kg p.o.), rat silk thread arterio-venous (AV) shunt (ED(50) 3.8 mg/kg p.o.), rat thromboplastin-induced AV shunt (ED(50) 3.1 mg/kg p.o.), rat carotid artery thrombosis (ED(200) 5.9 mg/kg p.o.), and rabbit venous thrombosis (ED(50) 7.5 mg/kg p.o.). Administered as an i.v. bolus, SSR182289A showed antithrombotic activity in the above models with ED(50)/ED(200) values in the range of 0.2 to 1.9 mg/kg i.v. SSR182289A increased rat tail transection bleeding time at doses > or =10 mg/kg p.o. In the rat thromboplastin-induced AV shunt model, SSR182289A 10 mg/kg p.o. produced marked antithrombotic effects at 30, 60, 120, and 240 min after administration. Hence, SSR182289A demonstrates potent oral antithrombotic properties in animal venous, AV-shunt, and arterial thrombosis models.
authors.affiliation: Sanofi-Synthélabo Research, Cardiovascular-Thrombosis Research Department, Chilly-Mazarin and Toulouse, France.
authors.forename: J
authors.initials: J
authors.lastname: Lorrain
authors.forename: L
authors.initials: L
authors.lastname: Millet
authors.forename: I
authors.initials: I
authors.lastname: Lechaire
authors.forename: S
authors.initials: S
authors.lastname: Lochot
authors.forename: P
authors.initials: P
authors.lastname: Ferrari
authors.forename: C
authors.initials: C
authors.lastname: Visconte
authors.forename: M
authors.initials: M
authors.lastname: Sainte-Marie
authors.forename: C
authors.initials: C
authors.lastname: Lunven
authors.forename: C N
authors.initials: CN
authors.lastname: Berry
authors.forename: P
authors.initials: P
authors.lastname: Schaeffer
authors.forename: J-M
authors.initials: JM
authors.lastname: Herbert
authors.forename: S E
authors.initials: SE
authors.lastname: O'Connor
mesh_terms: D000284:Administration, Oral; D000631:Aminopyridines / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D001760:Bleeding Time / Q000706:statistics & numerical data; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D005343:Fibrinolytic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D011817:Rabbits; D051381:Rats; D017207:Rats, Sprague-Dawley; D013449:Sulfonamides / Q000494:pharmacology* / Q000627:therapeutic use; D013917:Thrombin / Q000037:antagonists & inhibitors* / Q000502:physiology; D013927:Thrombosis / Q000188:drug therapy / Q000503:physiopathology
chemical_list: D000631:Aminopyridines; D005343:Fibrinolytic Agents; C469682:N-(3-((((4-(5-amino-2-pyridinyl)-1-((4-difluoromethylene)-1-piperidinyl)carbonyl)butyl)amino)sulfonyl)(1,1'-biphenyl)-2-yl) acetamide; D013449:Sulfonamides; D013917:Thrombin